79results about How to "Increased cost of treatment" patented technology

Methods of processing a fluid recovered from an oil or gas extraction operation for reuse in a hydraulic fracturing fluid are described. The methods include providing an amount of a produced fluid composition containing iron and suspended solids and controlling at least one of the conductivity, iron content, oxidative strength, and pH of the composition, such that Fenton's reagent is formed in situ. Also described are hydraulic fracturing fluids produced using fluid recovered from an oil or gas production process and treated in accordance with the methods described herein as well as systems for preparing a hydraulic fracturing fluid having, as a fluid source, fluid recovered from an oil or gas production process that has been treated in accordance with the methods described herein.

The invention relates to a method and device for treating or preventing or suppressing a disease or condition in a non-human animal. The method comprises the steps of providing a single delivery device containing two components for sequential delivery from the delivery device. A first component is delivered from the single delivery device into a teat canal of a non-human animal and subsequently the second component is delivered from the single delivery device into the teat canal. The components are delivered without substantial mixing of the components.

A substrate treatment apparatus is provided with a treatment bath (1) composed of a bottomed container which is surrounded by side walls (2b-2e) on the four sides and is open at the top, and first and second supplying nozzle tubes (10a-10d) which supply the treatment bath (1) with a treatment solution. The first and second supplying nozzle tubes (10a-10d) are composed of supplying nozzle tubes having a plurality of jetting ports (11) arranged on one line at prescribed intervals on each side plane in a longitudinal direction of the hollow tube-shaped body. The jetting ports of the first supplying nozzle tubes (10b, 10d) among the nozzle tubes are inclined diagonally downward at a prescribed angle from the horizontal direction, the jetting ports of the second supplying nozzle tubes (10a, 10c) are inclined diagonally upward at a prescribed angle from the horizontal direction, and the supplying nozzle tubes are arranged substantially horizontal at prescribed intervals on one side wall plane (2b) of the treatment bath (1). Stagnation of the treatment solution in the treatment bath is eliminated, uniform substrate treatment is made possible and furthermore, particle removal is facilitated.

The invention belongs to the filed of medicine and discloses a pharmaceutical composition using fimasartan and rosuvastatin or medicinal salt thereof as active components, wherein a mass ratio of rosuvastatin or medicinal salt thereof to fimasartan is 1:0.25-250 and preferably 1:10-100. The pharmaceutical composition containing rosuvastatin medicinal salt thereof and fimasartan has obvious synergism on treating hypertension and complications thereof, low treatment cost, little side-effect and good clinic application prospect.

The present invention relates to one composition for preventing and treating cardiac and cerebral vascular diseases and the composition may be used as medicine, health food or health food additive. The composition consists of red yeast and haw or haw leaf, and may contain gingko leaf and lotus leaf. The composition is used in preventing and treating hypertension, hyperlipemia, etc causing cardiac and cerebral vascular diseases, and has determined curative effect and no toxic side effect.

The present invention belongs to the field of screening antituberculotic target, vaccine antigen and detecting target in molecular biological technology, and is especially process of screening protein resisting rifampicin as antituberculotic. The process includes the first culturing drug resistant strain, the subsequent separating protein of drug resistant strain from protein of sensitive strain, comparing protein of drug resistant strain and protein of sensitive strain to determine the drug resistant protein, and final separating and identifying drug resistant protein. The process of the present invention can separate and identify drug resistant protein of Mycobacterium tuberculosis to provide new way for further understanding the drug resisting mechanism of Mycobacterium tuberculosis, fast clinical detection of drug resistant strain, and developing vaccine and medicine.

The invention discloses a pharmaceutical composition for treating a heart failure with preserved ejection fraction. The pharmaceutical composition comprises two active components: (1) activity factors of mitochondria acetaldehyde dehydrogenase 2 enzymatic activity; and (2) a nitrate medicine. According to the pharmaceutical composition, left ventricular end diastolic pressure is effectively reduced; the symptom of myocardial hypertrophy of a heart failure patient is improved; the heart failure with preserved ejection fraction is treated; meanwhile, the tolerance of the nitrate medicine when the heart failure with preserved ejection fraction is effectively reduced; and the effective dose of each single medicine is reduced, so that the incidence rate of the side effect of the medicine is relatively low; the treatment cost is also reduced; the benefit / cost ratio of treatment is obviously improved; the compliance of a patient is increased; the living quality is obviously improved.

The invention provides a discharge gas treatment apparatus and method which prevent increase in treatment cost and which attain efficient removal of mercury contained in a discharge gas. The discharge gas treatment apparatus, for treating a discharge gas containing nitrogen oxide, sulfur oxide, metallic mercury, and hydrogen chloride, includes a cooling apparatus for controlling the temperature of the discharge gas to a predetermined temperature in accordance with the hydrogen chloride concentration of the discharge gas; an NOx removal catalyst unit for reducing nitrogen oxide contained in the discharge gas for removal thereof and for causing reaction between mercury and hydrogen chloride contained in the discharge gas to thereby form mercury chloride, the discharge gas having been controlled to the predetermined temperature and having been introduced to the apparatus, with ammonia being added thereto; and a wet-format desulfurization apparatus, disposed on the downstream side with respect to the NOx removal catalyst unit, for removing sulfur oxide and mercury chloride contained in the discharge gas through dissolving sulfur oxide and mercury chloride in a liquid absorbent. The apparatus has a simple structure and prevents an increase in treatment cost.

The invention relates to a method and device for treating or preventing or suppressing a disease or condition in a non-human animal. The method comprises the steps of providing a single delivery device containing two components for sequential delivery from the delivery device. A first component is delivered from the single delivery device into a teat canal of a non-human animal and subsequently the second component is delivered from the single delivery device into the teat canal. The components are delivered without substantial mixing of the components.

A wastewater treatment device has: an ozone generator which supplies ozone; a mixer which mixes ozone supplied from the ozone generator with wastewater and supplies ozone mixed wastewater; an ozone oxidation unit which progresses ozone oxidation in the ozone mixed wastewater while passing the ozone mixed wastewater therethrough and discharges wastewater in which the ozone has been consumed; a biological treatment unit which performs biological treatment on the wastewater discharged from the ozone oxidation unit using microorganisms; and an adjusting device which adjusts the amount of ozone to be mixed with the wastewater by the mixer so that ozone in an amount that inhibits the microorganisms of the biological treatment unit does not remain in the wastewater discharged from the ozone oxidation unit.

The invention provides a sustained and controlled release preparation for a pharmaceutical composition for curing hypertension. The sustained and controlled release preparation composition includes a specific proportion of levamlodipine and angiotensin II receptor blocking pharmacon, wherein the levamlodipine is taken as the sustained and controlled release part and the angiotensin II receptor blocking pharmacon is taken as the common release part. The provided sustained and controlled release preparation enhances the therapeutic effect and reduces the treatment risk of the patients.

The invention provides an anti-alopecia hair-growing hair-blacking and hair-nourishing liquid and a manufacture method, and belongs to the technical field of traditional Chinese medicines. The anti-alopecia hair-growing hair-blacking and hair-nourishing liquid is prepared from the following raw materials in parts by weight: 10-15 parts of radix polygoni multiflori praeparata, 10-15 parts of cacumen platycladi, 5-10 parts of rhizoma zingiberis recens, 4-8 parts of herba ecliptae, 4-8 parts of fructus ligustri lucidi, 4-8 parts of radix rehmanniae praeparata, 4-8 parts of mori fructus, 4-8 partsof ginseng radix, 4-8 parts of rhizoma gastrodiae, 4-8 parts of radix astragali, 4-8 parts of radix angelicae sinensis, 4-8 parts of rhizoma chuanxiong, 4-8 parts of stigma croci, 4-8 parts of cortexdictamni, 4-8 parts of herba portulacae and 4-8 parts of rubiae radix. Ethyl alcohol and water are taken as solvents, the anti-alopecia hair-growing hair-blacking and hair-nourishing liquid is manufactured by a cold leaching method and has an obvious curative effect on symptoms, including alopecia, leukotrichia and the like caused by various reasons, and after the anti-alopecia hair-growing hair-blacking and hair-nourishing liquid is used for a long time, the hair is black and beautiful and is full of resilience. The anti-alopecia hair-growing hair-blacking and hair-nourishing liquid has a simple manufacture technology and a low cost, is quick to take effects, does not contain hormones or chemical ingredients, does not have toxic or side effects and has a wide applicable range.

A transcranial magnetic stimulation (TMS) coil positioning device includes a stimulation coil (1), a coil position tracking module (2), a head fixing frame (3), a head position tracking module (4), athree-dimensional mobile seat (5), a camera (6), a coil rotating device (7), a control system (8), an image processing module (9), an electromagnetic field calculation module (10), and a display (11).The image processing module (9) reconstructs the three-dimensional head model of a patient in an image space. The electromagnetic field calculation module (10) obtains the optimal coil position and angle by inversion according to the position of a nerve fiber to be activated in a target treatment target area. The control system (8), by means of the camera (6), the coil position tracking module (2), the coil rotating device (7), the head position tracking module (4), the head fixing frame (3) and the three-dimensional mobile seat (5), adjusts the relative position and angle of the stimulationcoil (1) and a patient head (12) to a target position and a target angle.

The invention discloses an orthopedics department deformity correction and bone fracture reduction fixing device and a processing method of the fixing device. The fixing device comprises an outer fixing frame or an outer fixing plate, wherein the outer fixing frame or the outer fixing plate is used for fixing needles inserted into the bone tissue, at least one end of the fixing needles is exposed out of the skin, in addition, the end part, exposed out of the skin, of the fixing needles is the end to be fixed, the outer fixing frame comprises a first fixing frame body and a second fixing frame body, the outer fixing plate is a fixing plate used for fixing all of the fixing needles inserted into the bone tissue to be fixed, and the outer fixing plate comprises one or several fixing plate blocks. The processing method comprises the following steps of image information collection before reduction, computer virtual reduction, fixing device structural design and fixing device processing. The fixing device provided by the invention has the advantages that the automatic reduction function is realized, the structure is reasonable, the fixation effect is good, and the defects of reduction deformity correction difficulty, surgery operation complexity, overdependence on the clinic experience of doctors and the like in the existing bone fracture reduction or deformity correction process can be effectively overcome.

The invention discloses a pharmaceutical composition for treating or preventing diabetes or its complications and an application thereof, and belongs to the medical field. According to the pharmaceutical composition, an insulin sensitizer and bromocriptine or its medicinal salt are used as active pharmaceutical ingredients. When the pharmaceutical composition is used to treat or prevent diabetes or its complications, the medical action modes are complementary. Therefore, the pharmaceutical composition shows remarkable synergism in the hypoglycemic aspect, has low adverse reaction, requires a low price and has a good application prospect.

The invention relates to application of an artemisia leaf extract, and in particular relates to application of an artemisia leaf extract in a medicament for treating pulmonary heart diseases and a preparation method of the artemisia leaf extract. The invention discloses the application of the artemisia leaf extract in preparing the medicament for treating the pulmonary heart diseases. The pulmonary heart diseases have the characteristics of high epidemicity, high morbidity rate, high death rate and high cost, and surveys show that the morbidity rate of people living in rural areas in northern China is 0.44%, therefore, the development of a pulmonary heart disease Chinese traditional medicine treatment medicament with a definite curative effect, a reasonable cost and sufficient supply of goods is of great significance. Meanwhile, the traditional Chinese medicament namely artemisia leaf is further developed and studied, and is finally pushed to the market, which also is one of important paths of realizing modernization of Chinese medicaments.

The invention belongs to the technical field of medicine healthcare and particularly relates to a compound essential oil for adjutant therapy of burns and scalds. The compound essential oil for adjutant therapy of burns and scalds is mainly prepared from the following components in percentage by weight: 80-95% of mealworm oil, 1-3% of thyme essential oil, 0.5-1% of clove essential oil, 1-2% of chamomile essential oil and 5-15% of grape seed oil. The invention aims to solve the problems of slowness for wound healing, easiness for infection, high treatment expense and scars remained after healing, which are caused by the fact that the burns and the scalds are mainly treated by using drugs at present.

The invention discloses an oral pharmaceutical composition for treating or preventing obesity-related hypertension and its application and belongs to the field of medicine. The pharmaceutical composition comprises orlistat and lol-suffixed pharmaceutical active ingredients. The usage of orlistat and lol-suffixed pharmaceuticals in the pharmaceutical composition is greatly reduced, thus the risk of pharmaceuticals injuring the human body is reduced. The oral pharmaceutical composition has significant synergistic effect in treating or preventing obesity-related hypertension, can reduce the weight of a patient and the risk of hypertension being complicated by cardiovascular diseases and has higher social value.

The present invention discloses a medicine combination for remedying the arthralgia due to rheumatism. The combination consists of white mustard seed, galangal, long pepper, red peony root, garden balsam seed, pricklyash peel, cassia twig, dried ginger, gamboges, nux vomica, pseudo ginseng root, os draconis, asarum, cinnamon, clove, dragon blood and dahurian angelica root. The medicine combination of the present invention can promote blood circulation for dissolving stasis to eliminate damaged tissue swelling, so as to ensure that intervertebral disc fibrous ring shrinks to recover automatically; the pressure of nerve root is released to dissolve pain and restore destroyed fibre, which not only can avoid the pain caused by operation and the large amount of treatment expense, but also the treatment time is short, and recrudesce and rebound can not occur.

The present invention provides an aqueous solution evaporative treatment method that makes it possible to efficiently perform evaporative treatment of a silica-containing aqueous solution. The aqueous solution evaporative treatment method comprises a seed crystal mixing step of adding to and mixing with a silica-containing aqueous solution a silicate as seed crystals and an evaporative concentration step of evaporatively concentrating the aqueous solution together with the seed crystals. The silicate is preferably magnesium silicate and / or calcium silicate.

The invention discloses a medicament for treating inferior turbinate hypertrophy and a method for preparing the same. The medicament for treating the inferior turbinate hypertrophy consists of the following components in part by weight: 8 to 25 parts of musk, 10 to 20 parts of ephedra herb, 5 to 15 parts of biond magnolia flower, 5 to 15 parts of Chinese honeylocust fruit, 5 to 15 parts of sandwort, 10 to 25 parts of fried siberian cocklour fruit, 5 to 15 parts of euphorbia kansui, 5 to 15 parts of pangolin scales and 10 to 25 parts of Chinese angelica. The method comprises the following steps of: fully mixing the medicaments; drying and pulverizing the medicaments to be 120 meshes; boiling the powder at the temperature of between 100 and 110 DEG C and sterilizing the powder for 10 to 30 minutes; and adding moisture burn ointment in an amount which is equal to the weight of the sterilized powder into the sterilized powder and mixing the mixture uniformly. The medicament for treating the inferior turbinate hypertrophy has the advantages of economy, practicability, no use of oral medicament, no need of operation, injection or puncture, no bleeding, no pain, no damage to mucosa of nasal cavity; the patient needs not to stay in hospital and can go home immediately without affecting the work and study; and the medicament can also be used for treating chronic rhinitis, sinusitis and allergic rhinitis while treating the inferior turbinate hypertrophy.

The invention discloses a dedicated primer for auxiliarily detecting a NDM-1 (New Metallo-Beta-Lactamase-1) gene and application thereof. The dedicated primer for auxiliarily detecting the NDM-1 (New Metallo-Beta-Lactamase-1) gene, provided by the invention, consists of DNA (deoxyribonucleic acids) shown by a sequence 1, a sequence 2, a sequence 3, a sequence 4, a sequence 5 and a sequence 6 in asequence table; and the NDM-1 protein is protein consisting of amino acid sequences shown in a sequence 7. The dedicated primer has the characteristics of high sensitivity, high speed, strong specificity, simpleness and convenience, safety, and the like while used for detection, can be widely applied to improve the pathogenic microorganism detection capability of a low apparatus location area, and has great significance for early and accurate diagnosis of pathogenic microorganisms. The dedicated primer can not only be used for guiding clinical reasonable medication and avoiding from delaying illness and increasing treatment expenses, but also is beneficial to controlling propagation of the pathogenic microorganisms and preventing outbreak, thereby having important significance for improving the treatment effect and controlling infection in hospitals.

A method to remove toxic heavy metals soluble in wastewaters of household or industrial origin that comprises the phases of:Providing lignocellulosic material with low moisture (10% or less) which is subject to grading reduction with a size below 1 mm;Defining a solid-liquid ratio in an adsorption reactor where its value depends on the liquid residue composition to be treated within a 3 and 50 g / L interval.Placing the liquid to be treated and the lignocellulosic material in said adsorption reactor at room temperature.Stirring and adjusting the pH value during the process, where said pH depends on the composition of the liquid residue to be treated. The pH value is adjusted within an interval of pH 3 through pH 8.Keeping the liquid to be treated under turbulent stirring with the vegetal substrate inside the reactor until the concentration values desired for the metallic composition of the aqueous composition are achieved.Use of lignocellulosic material of natural origin, such as wastes of timber and / or cellulose industry and agricultural industry, by-products of the forest industry, industry of grains to remove toxic heavy metals soluble in waste waters.

The invention belongs to the technical field of medicine, and specifically discloses a medicine for treating diabetes and its application. It consists of the following raw materials in terms of weight fraction: 5-10 parts of glibenclamide, 15-20 parts of ginkgo extract, and 5 parts of bromocriptine -10 parts, 10-15 parts of dextrin, 0.1-0.5 parts of malic acid, 1-5 parts of glycyrrhizin, 0.1-0.5 parts of magnesium stearate and 5-10 parts of microcrystalline cellulose. The medicine for treating diabetes of the present invention can effectively solve the problem that type 2 diabetes cannot be effectively controlled by taking common hypoglycemic medicine alone in the prior art, and has the effects of controlling blood sugar, synergistically protecting endothelial cell function, reducing diabetic complications and the like.

Compounds, compositions, methods, and uses are described herein for the treatment of respiratory diseases, including cystic fibrosis. Inhalation formulations of macrolide antibiotics are also described herein. The treatment of bacterial infections continues to be an important endeavor of pharmaceutical research and development. The specter of bacterial resistance to currently available antibiotics is ever-present, and accordingly, new and improved compounds, pharmaceuticals formulations, treatment methods, and treatment protocols are needed.

The invention belongs to the field of medicine preparations, which relates to a medicine composition containing the active components of levorotatory amlodipine / amlodipine and losartan. Concretely, the medicine composition is an osmotic pump preparation. The osmotic pump preparation contains main medicines, high molecular substances, a surfactant, an osmotic pressure promoter, an osmosis promotion polymer and auxiliary materials of other conventional preparation tablets and a coating. The medicine composition represents an obvious advantage in the indexes of the pressure relief, the sugar tolerance, the urine content of urine trace albumin, blood leucocyte after stress and the like.